• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Patient Selection for Amyloid-Targeting Therapies: Key Characteristics and Considerations

Opinion
Video

Panelists discuss how ideal candidates for amyloid-targeting therapy typically present with biomarker-confirmed early-stage Alzheimer disease, demonstrate positive amyloid PET scans or CSF biomarkers, exhibit mild cognitive impairment or mild dementia, lack contraindications such as significant cerebrovascular disease or anticoagulant use, have adequate support systems for monitoring and managing potential adverse effects, and would benefit from comprehensive pretreatment evaluations including brain MRI and APOE genotyping.

Related Videos
Galen Shearn-Nance, BS, and Johnie Rose, MD, PhD
4 experts are featured in this series.
1 expert is featured in this series.
4 experts are featured in this series.
Galen Shearn-Nance, BS
4 experts are featured in this series.
5 experts are featured in this series
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.